Author name: admin22

FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer

On November 17, 2026, the Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine …

FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer Read More »

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

On November 16, 2026, the Food and Drug Administration approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, …

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer Read More »

iPLEDGE REMS Modifications Have Been Implemented and Are Live for Isotretinoin, a Medication for Severe Acne

The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) modifications were implemented yesterday, November 15, 2026. The iPLEDGE REMS is a safety program to mitigate the risk of isotretinoin, which can result in harm to fetal development. Isotretinoin is approved to treat severe nodular acne that has not responded to other treatments in non-pregnant patients 12 years and older.

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy. Gazyva was previously approved for treating certain …

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy Read More »

FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

On November 13, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for or who have refused cisplatin based chemotherapy.

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition

The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision …

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition Read More »

FDA Request for Information — Patient-Level Data for RWD/RWE Submissions (Docket No. FDA-2026-N-10742)

The U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) are aware of challenges sponsors encounter in submitting patient-level data for real-world data (RWD) analyzed as part of clinical studies in a marketing application. These challenges relate to data ownership, privacy requirements (including …

FDA Request for Information — Patient-Level Data for RWD/RWE Submissions (Docket No. FDA-2026-N-10742) Read More »